rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Cancer Research

• Publication date

  2011-09-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-11-0647PMID 21918174PMCID PMC3622251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.

  2011cited by this paper
• Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells

  2011cited by this paper
• Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma: Complement/Rituximab Interactions & Clinical Results in Refractory CLL. Ann. N. Y Acad. Sci. 1173: 865-873

  2010cited by this paper
• Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study

  2010cited by this paper
• Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.

  2010cited by this paper
• Rituximab in chronic lymphocytic leukemia.

  2010cited by this paper
• Monoclonal antibody therapy of chronic lymphocytic leukaemia.

  2010cited by this paper
• Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

  2010cited by this paper
• In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

  2010cited by this paper
• U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

  2010cited by this paper
• Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma

  2009cited by this paper
• Update in the management of chronic lymphocytic leukemia

  2009cited by this paper
• Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

  2009cited by this paper
• Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.

  2009cited by this paper
• Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX1

  2009influential reference
• Complement Regulator CD59 Protects Against Atherosclerosis by Restricting the Formation of Complement Membrane Attack Complex

  2009cited by this paper
• An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy

  2009cited by this paper
• In vivo Model of Follicular Lymphoma Resistant to Rituximab

  2009cited by this paper
• A High-Affinity Inhibitor of Human CD59 Enhances Complement-Mediated Virolysis of HIV-1: Implications for Treatment of HIV-1/AIDS

  2009cited by this paper
• Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies.

  2008influential reference
• The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.

  2008influential reference
• Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis1

  2008cited by this paper
• Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.

  2008cited by this paper
• Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders.

  2008cited by this paper
• Neutralizing human antibodies against CD55 and CD59 targeted to lymphoma cells in vivo potentiate the therapeutic effect of Rituximab

  2007cited by this paper
• Mechanisms of killing by anti-CD20 monoclonal antibodies.

  2007cited by this paper
• ‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’

  2007cited by this paper
• Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.

  2006cited by this paper
• The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201

  2006influential reference
• Minimal Residual Disease in Ovarian Cancer as a Target for Complement‐Mediated mAb Immunotherapy

  2006cited by this paper
• Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement‐regulatory proteins CD55 and CD59

  2005cited by this paper
• A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation

  2005cited by this paper
• Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.

  2004cited by this paper
• Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia1

  2004cited by this paper
• In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

  2003cited by this paper
• Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

  2003cited by this paper
• An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.

  2003cited by this paper
• Rituximab in chronic lymphocytic leukemia.

  2003cited by this paper
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use only.

  2002cited by this paper
• CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.

  2001influential reference
• Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.

  2001cited by this paper
• Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies.

  2000cited by this paper
• Overexpression of protectin (CD59) down‐modulates the susceptibility of human melanoma cells to homologous complement

  2000cited by this paper
• Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

  2000cited by this paper
• Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms

  2000cited by this paper
• Complement‐regulatory proteins in ovarian malignancies

  1997cited by this paper
• Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer

  1997cited by this paper
• Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17‐1A

  1997cited by this paper

• CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells

  2024cites this paper
• Complement regulation in tumor immune evasion.

  2024cites this paper
• Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab

  2022influential citation
• Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis

  2021influential citation
• Cancer immunotherapy from biology to nanomedicine.

  2021cites this paper
• Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma

  2020cites this paper
• How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca2+

  2020cites this paper
• Monoclonal Antibodies for Cancer Immunotherapy

  2020cites this paper
• The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs

  2020cites this paper
• The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy

  2019cites this paper
• CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

  2018cites this paper
• A tale of two antibodies: obinutuzumab versus rituximab

  2018cites this paper
• Drug resistance in multiple myeloma.

  2018cites this paper
• CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.

  2016cites this paper
• Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies.

  2016cites this paper
• Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

  2015cites this paper
• Regulation of Complement Dependent Cytotoxicity by TGF-β-induced Epithelial-Mesenchymal Transition

  2015cites this paper
• Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells

  2015cites this paper
• Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack

  2015cites this paper
• Monoclonal Antibodies for Cancer Immunotherapy

  2015cites this paper
• Mechanisms of host recognition and immune evasion of members of the Streptococcus anginosus/milleri group.

  2015cites this paper
• Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP.

  2014cites this paper
• Protein engineering to target complement evasion in cancer

  2014cites this paper
• Increased CD59 protein expression is associated with the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP

  2014cites this paper
• Surface Levels of CD20 Determine Anti-CD20 Antibodies Mediated Cell Death In Vitro

  2014influential citation
• The role of complement in mAb-based therapies of cancer.

  2014cites this paper
• Complement and HIV-I infection/HIV-associated neurocognitive disorders

  2014cites this paper
• Rapid Degradation of the Complement Regulator, CD59, by a Novel Inhibitor*

  2014influential citation
• Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

  2014cites this paper
• The making of a macromolecular machine: assembly of the membrane attack complex.

  2014cites this paper
• Complement-Dependent Cancer Cell Lysis in Humans Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated

  2013cites this paper
• CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I

  2013cites this paper
• Construction of an improved drug delivery system tool with enhanced versatility in cell-targeting.

  2013cites this paper
• Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies.

  2013cites this paper
• Progress and Trends in Complement Therapeutics.

  2013cites this paper
• Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

  2013cites this paper
• Combination of two anti‐CD5 monoclonal antibodies synergistically induces complement‐dependent cytotoxicity of chronic lymphocytic leukaemia cells

  2013cites this paper
• Neuroblastoma: developmental biology, cancer genomics and immunotherapy

  2013cites this paper
• Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement

  2013cites this paper
• Loss of CD20 expression in relapsed diffuse large B cell lymphoma after rituximab therapy: a case report and review of the literature

  2013cites this paper
• Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells

  2013influential citation
• Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.

  2013cites this paper
• Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans

  2013cites this paper
• Combination with Chemotherapy Leukemia Cells in Whole Blood and in Rituximab in Lysing B Chronic Lymphocytic Ofatumumab Is More Efficient than

  2012cites this paper
• Removal of the tag from His-tagged ILYd4, a human CD59 inhibitor, significantly improves its physical properties and its activity.

  2012cites this paper
• Current world literature.

  2006cites this paper